# Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B

> **NCT00922792** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 8 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A
- Haemophilia B

## Interventions

- **DRUG:** activated recombinant human factor VII, long acting
- **DRUG:** activated recombinant human factor VII, long acting

## Key facts

- **NCT ID:** NCT00922792
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922792, "Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00922792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*